SynthesisBMC women's health2025
Prognostic value of lymphocyte-to-monocyte ratio for breast cancer: a systematic review and meta-analysis.
Synthesis in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Physical activity and cancer survival: the role of peripheral blood immune and inflammatory markers in reducing mortality-a retrospective cohort study based on NHANES 1999-2018.Translational cancer research · 2026Article
- Prognostic value of pre-treatment serum CA19-9 and lymphocyte-to-monocyte ratio in HR+/HER2- breast cancer: a retrospective cohort study.BMC cancer · 2026Article
- Clinical and hematological indices as prognosticators in localized solitary fibrous tumors: A retrospective study.Therapeutic advances in medical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe incidence of breast cancer has been ascending. The lymphocyte-to-monocyte ratio (LMR) has been reported as a prognostic factor for breast cancer. This meta-analysis aimed to assess the predictive significance of LMR in breast cancer.
methodPubMed, Embase, Cochrane, and Web of Science were searched for relevant articles on the predictive significance of LMR in breast cancer up to May 2024. The hazard ratio (HR) of overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), and distant metastasis-free survival (DMFS) was calculated using fixed-effects or random-effects models. The LMR threshold and follow-up information were extracted, and subgroup analyses were performed.
resultTwenty-two studies were included in the meta-analysis. LMR accurately predicted OS, DFS, and RFS in breast cancer (p < 0.05), with high LMR associated with improved outcomes. However, the association between higher LMR and longer DMFS in breast cancer was uncertain. LMR's predictive value for OS and DFS remained significant in different regions, sample size, LMR threshold, follow-up, and timing. The predictive effect of LMR were different in different molecular subtypes of breast cancer.
conclusionThis meta-analysis identified the prognostic value of LMR for OS and DFS in breast cancer. However, selection bias existed due to the predominance of retrospective studies, and considerable heterogeneity was observed for some indicators. Further research is necessary to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.